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Summary
Background: The optimal duration of triple anti-platelet therapy (DTAP) remains unclear in
patients with acute myocardial infarction (AMI).
Methods: We retrospectively analyzed 716 AMI patients who received TAP (aspirin, clopido-
grel, and cilostazol) after drug-eluting stent (DES) implantation from November 2005 to May
2008. Mean age was 61.9± 11.70 years (male gender 74.1%) and mean duration of TAP was
98.1± 115.34 days. We compared the major adverse cardiovascular events [MACE, deﬁned
as the composite of cardiac death, non-fatal AMI, stent thrombosis, and target vessel revas-
cularization (TVR)] between the group of DTAP ≥3 months (n = 497) and those of <3 months
(n = 219).
niﬁcant differences in the incidences of cardiac death, non-fatalResults: There were no sig
AMI, stent thrombosis, and TVR at 1-year follow-up between the two groups. However, the
group of DTAP ≥3 months had lower incidence of MACE than those <3 months (5.9% vs. 10.7%,
p = 0.044). The rate of bleeding complications was similar between the two groups. By Cox
regression analysis with propensity score adjustment, Killip class IV and DTAP ≥3 months were
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independent predictors of 1-year MACE [hazard ratio (HR) = 10.417; 95% conﬁdence interval
(CI) = 1.587—68.377, p = 0.015 and HR= 0.508; 95% CI = 0.269—0.956, p = 0.036].
Conclusions: Our data show that the DTAP ≥3 months is associated with better clinical outcomes
compared with that of <3 months in patients with AMI undergoing DES implantation without
tions
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regression analysis using DTAP ≥3 months as the depen-
dent outcome variable and entering all baseline clinical,increasing bleeding complica
© 2011 Japanese College of C
ntroduction
rug-eluting stents (DESs) are well known to be safe and
fﬁcacious in the ‘‘real world’’ practice compared to bare
etal stents (BMSs) [1], even if patients suffered acute
yocardial infarction (AMI) [2—6]. However, DES was associ-
ted with an increased risk for stent thrombosis, especially
n patients with AMI [7,8]. Recent studies showed that triple
nti-platelet therapy (TAP) such as administration of cilosta-
ol with aspirin and clopidogrel seemed to be safe and
uperior to dual anti-platelet therapy (aspirin plus clopi-
ogrel) in patients with ST-segment elevation MI (STEMI)
r acute coronary syndrome undergoing stent implantation
9—11].
The American College of Cardiology/American Heart
ssociation (ACC/AHA) guidelines recommended that
atients with the acute coronary syndrome/non-ST-
egment elevation MI (NSTEMI) undergoing DES implantation
hould receive dual anti-platelet therapy with aspirin and
lopidogrel for at least 12 months [12]. However, the
ptimal duration of TAP varies and remains unclear. Some
atients were prescribed TAP for at least 1 month [9], but
thers for more than at least 6 months [13].
The aim of our study was to compare the clinical out-
ome based on the duration of TAP and evaluate the optimal
uration of TAP in patients with AMI undergoing DES implan-
ation.
ethods
tudy population
rom November 2005 to May 2008, we retrospectively
nrolled patients with AMI including both STEMI and NSTEMI
ho received TAP (aspirin + clopidogrel + cilostazol) after
rimary DES implantation at Chonnam National University
ospital. We excluded patients who had suffered major
dverse cardiovascular events (MACE) within 3 months after
ndex procedure. Patients were divided into two groups
ased on the duration of triple anti-platelet therapy (DTAP)
f 3 months, because mean DTAP of total patients was about
8 days.
ercutaneous coronary intervention and
edications
he emergent or early invasive treatments were deter-
ined based on the AMI patient status according to the
linical decision of operators. Following the insertion of a
atheter, the guide wire was placed across the occlusive or
tenotic lesions and DESs were implanted after prior balloon
ngioplasty. The type of DES was determined based on the
ecision of operators. Successful PCI was deﬁned as a target
a
m
m
w
ﬁ.
ology. Published by Elsevier Ltd. All rights reserved.
essel at the treatment site with antegrade Thrombolysis In
yocardial Infarction (TIMI)-3 ﬂow and angiographic residual
tenosis less than 50% following the implantation of stents.
nti-platelet agents were administered to all patients prior
o the intervention, with aspirin 300mg and clopidogrel
00—600mg. After the intervention, the patients received
00mg of aspirin per day indeﬁnitely and 75mg of clopido-
rel per day for at least one year. Cilostazol was given to
atients after the intervention. Following a 200-mg load-
ng dose, the patients received 200mg of cilostazol per
ay (100mg b.i.d.) and stopped receiving it based on the
atient status in accordance with the subjective decision of
hysicians. Other medical treatments including angiotensin-
onverting enzyme inhibitors (ACEi), angiotensin-II receptor
lockers (ARB), beta-blockers, calcium channel blockers,
nd lipid lowering agents were also used based on the
tandard treatment regimen for patients with AMI in a non-
estrictive manner.
ollow-up and clinical outcomes
atients were recommended to visit the outpatient clinic
ne month after discharge and once every 2—3 months
hereafter. In lost to follow-up cases, the clinical course
as monitored through a telephone call by specialized per-
onnel. The primary endpoint was the incidence of MACE,
eﬁned as cardiac death, non-fatal MI, stent thrombosis, and
arget vessel revascularization (TVR). The secondary end-
oints were the incidence of safety endpoints, deﬁned as
ardiac death, non-fatal MI, and stent thrombosis within the
-year follow-up after index procedure and bleeding com-
lications at 1-year follow-up. Stent thrombosis was deﬁned
s only deﬁnite stent thrombosis according to the criteria
f the Academic Research Consortium (ARC). Bleeding rates
ere also deﬁned based on the TIMI bleeding classiﬁcation
14].
tatistical analysis
ategorical variables were expressed as a frequency and
ontinuous variables as mean± SD (SD: standard deviation).
n analysis of categorical variables was performed using
hi-square test or Fisher’s exact test and that of continu-
us ones using Student’s t-test. A propensity score analysis
as accomplished by performing a multivariable logisticngiographic, procedural characteristics, and concomitant
edications that would affect the probability of DTAP ≥3
onths. Multivariate Cox regression analysis was performed
ith adjustments for the propensity score [15] and identi-
ed with the independent factors affecting the incidence
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Table 1 Baseline clinical characteristics according to duration of triple anti-platelet therapy.
DTAP <3 months (n = 497) DTAP ≥3 months (n = 219) p-Value
Mean DTAP, days 34.10± 20.78 243.26± 110.20 <0.001
Age, years 62.64± 11.32 60.06± 12.34 0.006
Male gender 357 (71.8) 175 (79.9) 0.023
Hypertension 225 (45.3) 99 (45.2) 0.987
Diabetes 136 (27.4) 76 (34.7) 0.047
Dyslipidemia 20 (4.0) 9 (4.1) 0.957
Current smoker 217 (43.7) 113 (51.6) 0.050
Family history of CAD 24 (4.8) 10 (4.6) 0.879
History of IHD 53 (10.7) 33 (15.1) 0.095
Killip class on admission 0.188
I 409 (82.3) 187 (85.4)
II 42 (8.5) 15 (6.8)
III 34 (6.8) 8 (3.7)
IV 12 (2.4) 9 (4.1)
Left ventricular ejection fraction, % 55.84± 11.80 56.90± 11.01 0.262
Creatinine clearance, ml/min 71.29± 28.76 75.06± 29.03 0.019
Stage of CKD 0.221
Stage 1 108 (21.9) 64 (29.5)
Stage 2 210 (42.5) 83 (38.2)
Stage 3 152 (30.8) 57 (26.3)
Stage 4 18 (3.6) 10 (4.6)
Stage 5 6 (1.2) 3 (1.4)
Diagnosis 0.221
ST elevation MI 331 (66.6) 156 (71.2)
Non-ST elevation MI 166 (33.4) 63 (28.8)
Concomitant medications
Beta-blockers 384 (77.3) 178 (81.3) 0.228
ACE inhibitors 362 (72.8) 155 (70.8) 0.571
ARBs 77 (15.5) 36 (16.4) 0.749
Calcium channel blockers 30 (6.0) 9 (4.1) 0.295
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Data are n (%), or mean± SD. DTAP, duration of triple anti-platele
CKD, chronic kidney disease; MI, myocardial infarction; ACE, angi
of MACE following TAP after the implantation of DES in
patients with AMI. All the statistical analyses were per-
formed using SPSS (Statistical Package for Social Science,
SPSS Inc., Chicago, IL, USA) for Windows, Version 15.0. A
value of p < 0.05 was considered statistically signiﬁcant.
Results
Patients’ baseline characteristics
We enrolled 714 AMI patients who received TAP after pri-
mary DES implantation. Mean age of the enrolled patients
was 61.9± 11.70 years (male gender 74.1%) and mean dura-
tion (MD) of TAP was 98.1± 115.34 days. The enrolled
patients were divided in two groups as follows: the group
of patients with DTAP of less than 3 months (the DTAP
<3 months; n = 497, MD= 34.1± 20.78 days) and the group
of patients with DTAP of 3 months or more (the DTAP ≥3
months; n = 219, MD= 234.3± 110.20 days). The mean age
and creatinine clearance were signiﬁcantly higher in the
s
n
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c
p181 (82.6) 0.296
rapy; CAD, coronary artery disease; IHD, ischemic heart disease;
in-converting enzyme; ARBs, angiotensin receptor blockers.
TAP <3 months than in the DTAP ≥3 months, while male
ender and history of diabetes were more frequent in the
TAP ≥3 months than in the DTAP <3 months. However,
here were no differences in the other baseline clinical
haracteristics (Table 1). There were also no signiﬁcant
ifferences in angiographic and procedural characteristics
etween the two groups except paclitaxel-eluting stents
ere predominantly used in the DTAP ≥3 months and
otarolimus-eluting stents were more common in the DTAP
3 months (Table 2).
ollow-up clinical outcomes
ll patients were clinically followed up at 12 months. Of
hese patients, 386 patients (53.9%) were able to perform
ollow-up angiography within 12 months. There were no
igniﬁcant differences in the incidences of cardiac death,
on-fatal AMI, stent thrombosis, target lesion revascular-
zation, and TVR between the two groups during a 12-month
linical follow-up. However, the incidence of safety end-
oint and MACE were signiﬁcantly lower in the DTAP ≥3
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Table 2 Baseline angiographic and procedural characteristics according to duration of triple anti-platelet therapy.
DTAP <3 months (n = 497) DTAP ≥3 months (n = 219) p-Value
Infarct-related artery (%) 0.821
LAD 262 (52.7) 116 (53.0)
LCX 71 (14.3) 27 (12.3)
RCA 152 (30.6) 72 (32.9)
Left main 12 (2.4) 5 (1.8)
Diseased vessels (%) 0.973
Single vessel 242 (48.7) 107 (48.9)
Two vessels 141 (28.4) 59 (26.9)
Three vessels 83 (16.7) 39 (17.8)
Left main disease 31 (6.2) 14 (6.4)
ACC/AHA classiﬁcation (%) 0.944
Type A or B1 153 (30.8) 68 (31.1)
Type B2 or C 344 (69.2) 151 (68.9)
Preprocedural TIMI ﬂow grade (%) 0.301
0 202 (40.6) 98 (44.7)
I 22 (4.4) 14 (6.4)
II 131 (26.4) 57 (26.0)
III 142 (28.6) 50 (22.8)
Postprocedural TIMI ﬂow grade (%) 0.266
0 2 (0.4) 0 (0.0)
I 0 (0.0) 1 (0.5)
II 9 (1.8) 2 (0.9)
III 486 (97.8) 216 (98.6)
Type of stent used (%) 0.037
Paclitaxel-eluting 354 (71.2) 173 (79.0)
Sirolimus-eluting 82 (16.5) 32 (14.6)
Zotarolimus-eluting 61 (12.3) 14 (6.4)
Stent diameter at target lesion, mm 3.2± 0.36 3.2± 0.33 0.485
Stent length at target lesion, mm 25.3± 5.82 25.1± 5.65 0.757
Total number of stents 1.7± 0.98 1.8± 0.98 0.598
Use of glycoprotein IIb/IIIa inhibitor (%) 175 (35.2) 78 (35.6) 0.917
Data are n (%), or mean± SD. DTAP, duration of triple anti-platelet therapy; LAD, left anterior descending artery; LCX, left circum-
ﬂex artery; RCA, right coronary artery; ACC/AHA, American College of Cardiology/American Heart Association; TIMI, Thrombolysis In
Myocardial Infarction.
Figure 1 12-Month clinical outcomes according to DTAP of 3 months. The incidence of total death, the safety endpoint, and MACE
were signiﬁcantly lower in the DTAP ≥3 months compared with the DTAP <3 months. DTAP, duration of triple anti-platelet therapy;
MI, myocardial infarction; TLR, target lesion revascularization; TVR, target vessel revascularization; PCI, percutaneous coronary
intervention; EP, endpoint; MACE, major adverse cardiovascular events.
Duration of triple anti-platelet therapy in AMI 57
Table 3 Bleeding complications according to duration of triple anti-platelet therapy.
DTAP <3 months (n = 497) DTAP ≥3 months (n = 219) p-Value
Degree of bleeding according to TIMI criteria
Major 1 (0.2) 0 (0.0) 1.000
Minor 3 (0.6) 0 (0.0) 0.557
Minimal 5 (1.0) 3 (1.4) 0.706
Need for transfusion 40 (8.0) 13 (6.0) 0.327
Data are n (%). DTAP, duration of triple anti-platelet therapy; TIMI, Thrombolysis In Myocardial Infarction.
Figure 2 Kaplan—Meier survival curves for total death (A) and MACE (B) according to DTAP of 3 months. These curves demonstrated
signiﬁcant differences in freedom from total death and MACE between the two groups. DTAP, duration of triple anti-platelet therapy;
MACE, major adverse cardiovascular events.
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Table 4 Independent predictors of 1-year MACE in patients with acute myocardial infarction who received triple anti-platelet
therapy after drug-eluting stent implantation.
Variables HR 95% CI p-Value
Killip class IV (vs. class I) 10.417 1.587—68.377 0.015
DTAP ≥3 months 0.508 0.269—0.956 0.036
Current smoker 1.967 0.991—3.904 0.053
Use of glycoprotein IIb/IIIa inhibitor 0.602 0.337—1.075 0.086
ACC/AHA type B2/C lesion 1.757 0.920—3.353 0.088
History of ischemic heart disease 3.780 0.709—20.171 0.120
Diagnosed ST elevation MI 2.137 0.794—5.750 0.133
History of diabetes mellitus 2.320 0.645—8.340 0.197
Stage 5 of CKD (vs. stage 1) 2.806 0.579—13.589 0.200
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iMACE, major adverse cardiovascular events; HR, hazard ratio; C
ACC/AHA, American College of Cardiology/American Heart Associ
onths compared with the DTAP <3 months (0.9% vs. 3.8%,
= 0.033; 0.9% vs. 10.7%, p = 0.044) (Fig. 1).
There were no signiﬁcant differences in the incidences
f TIMI bleeding criteria or need for transfusion among the
groups during the follow-up period (Table 3).
Kaplan—Meier survival analysis demonstrated signiﬁcant
ifferences in freedom from death and MACE between the
wo groups (Fig. 2).
The Cox proportional regression analysis was performed
o identify the independent predictors for the occurrence
f 1-year MACE in AMI patients receiving TAP after DES
mplantation. Independent predictors for 1-year MACE in AMI
atients receiving TAP after DES implantation included Killip
lass IV on admission [hazard ratio (HR) = 10.417; 95% con-
dence interval (CI) = 1.587—68.377] and DTAP ≥3 months
HR = 0.508; 95% CI = 0.269—0.956) (Table 4).
iscussion
ur study was conducted to identify the optimal DTAP in AMI
atient undergoing DES implantation. The group of patients
ith DTAP of 3 months or more had signiﬁcantly lower inci-
ences of all-cause death, the safety endpoint, and MACE
ompared with the group of patients with DTAP of less than
months.
Therefore, DTAP ≥3 months is associated with bet-
er clinical outcomes in patients with AMI undergoing DES
mplantation without increasing bleeding complications.
While DES reduced the need for repeat revascularization
ithout an increase in death or MI, there tended to be an
ncreased risk of late stent thrombosis [16—18]. However,
ES implantation for AMI patients remained debatable, even
hough some studies have reported that it was safe and efﬁ-
acious compared to BMS implantation [2,3,19]. DES tended
o delay endothelialization, increasing the risk of stent
hrombosis. In particular, vessel healing at the culprit site in
MI patients with DES implantation is substantially delayed
ompared with the culprit site in patients with stable angina
20]. Therefore, AMI patients with DES implantation have
n increased risk of thrombotic complications such as MI
r stent thrombosis. To prevent thrombotic complications,
ual anti-platelet therapy was recommended for at least
2 months in patients with AMI after DES implantation [12].
p
e
i
t
iﬁdence interval; DTAP, duration of triple anti-platelet therapy;
; MI, myocardial infarction; CKD, chronic kidney disease.
ndeed, the addition of cilostazol to dual anti-platelet ther-
py was well known to have a beneﬁcial effect on the
revention of thrombotic complications.
Cilostazol selectively inhibits phosphodiesterase type III
hich is released from platelets, and it thereby raises the
ntracellular concentration of cAMP and calcium, therefore,
uppresses platelet aggregation and relaxes the vascular
mooth muscle cells, thus having anti-platelet, anti-
therosclerotic, anti-proliferative, and vasodilative effects
21—23]. The anti-platelet effect of cilostazol helps prevent
hrombotic complications in patients following stent implan-
ation [24]. In addition, a recent study demonstrated TAP
ncluding cilostazol could ameliorate platelet responsive-
ess to clopidogrel in patients undergoing stent implantation
25].
How long should cilostazol be given to prevent throm-
otic complications after DES implantation? The appropriate
uration of TAP involves balancing the effect of cardiovas-
ular protection and the risk of bleeding. Our study showed
TAP of more than at least 3 months was associated with
ower composite incidence of cardiac death, non-fatal MI,
r deﬁnite stent thrombosis without a signiﬁcant increased
leeding risk.
Iakovou et al. [26] reported that a total of 71% of
ubacute stent thrombosis occurred within 1 week of the
rocedure and more than 50% of late stent thrombosis cases
ccurred within 3 months of the procedure. However, our
tudy excluded patients who suffered MACE within 3 months,
n order to prevent the unintentional increase of MACE in
he DTAP <3 months. Therefore, our study was unable to
ssess the effect of TAP for MACE within 3 months of the
rocedure. However, considering that stent thrombosis fre-
uently occurred within 3 months of the procedure, our
pinion seemed to be proper that cilostazol should be given
or more than at least 3 months.
Cilostazol has been known to reduce restenosis after suc-
essful balloon angioplasty or stent implantation [27,28].
he reduction of restenosis was associated with the direct or
ndirect inhibitory effect of cilostazol on the migration and
roliferation of vascular smooth muscle cells [29,30]. How-
ver, it remains unclear how long should cilostazol be given
f the reduction of restenosis appears. Our study showed
hat there were no differences in target lesion revascular-
zation (TLR) or TVR rates between groups according to DTAP.
[[
[
[
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Acute lesions of patients with AMI may havemore thrombotic
burden and less ﬁbrous atheroma and may be less prone
to restenosis compared with stable plaques of those with
stable angina [31]. Therefore, the impact of TAP may not
be prominent in restenosis or TLR rates between DTAP in
patients with AMI. However, a large-scale prospective ran-
domized trial is needed to assess the reduction of restenosis
according to DTAP.
Study limitations
The main limitation of our study is that it was conducted as
a single-center, retrospective non-randomized comparative
one. This might have introduced a signiﬁcant bias in patient
selection, even though it was partially compensated for by
multivariate Cox regression model using propensity score to
control the baseline biases. It was another limitation that
there were few medical records about adverse reactions to
cilostazol and why the patients stopped taking cilostazol.
Also, each patient was very different in DTAP. Accordingly,
we were unable to deﬁne the exact optimal DTAP. It is the
other limitation that a regular follow-up coronary angiog-
raphy within 12 months was performed for approximately
53.9% of the patients. Most of TLRs were performed based
on the judgment of operators on a regular follow-up coro-
nary angiography rather than the ischemic symptoms. Owing
to this, the possibility for selection bias could not be com-
pletely ruled out.
Conclusion
Our data show that DTAP ≥3 months is associated with bet-
ter clinical outcomes than that of <3 months in patients
with AMI undergoing DES implantation without increasing
bleeding complications. However, large-scale, long-term,
prospective, randomized trials are needed to assess the
exact optimal DTAP in AMI patients.
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